Deutsche Bank AG Raises Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Deutsche Bank AG raised its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 311.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 171,602 shares of the company's stock after acquiring an additional 129,936 shares during the quarter. Deutsche Bank AG's holdings in Dr. Reddy's Laboratories were worth $2,710,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. AIA Group Ltd lifted its position in shares of Dr. Reddy's Laboratories by 441.7% during the 4th quarter. AIA Group Ltd now owns 145,150 shares of the company's stock valued at $2,292,000 after buying an additional 118,357 shares in the last quarter. Vanguard Group Inc. raised its stake in Dr. Reddy's Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after acquiring an additional 3,911,404 shares during the period. Robeco Institutional Asset Management B.V. lifted its holdings in Dr. Reddy's Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Dr. Reddy's Laboratories by 609.4% in the fourth quarter. Van ECK Associates Corp now owns 5,838 shares of the company's stock worth $92,000 after purchasing an additional 5,015 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Dr. Reddy's Laboratories by 400.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock worth $8,373,000 after purchasing an additional 427,573 shares during the period. Institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Price Performance

Shares of NYSE:RDY traded up $0.35 during trading on Tuesday, hitting $14.73. 1,444,637 shares of the company's stock were exchanged, compared to its average volume of 1,490,256. The business's 50-day simple moving average is $13.62 and its 200 day simple moving average is $14.01. The company has a market cap of $12.30 billion, a price-to-earnings ratio of 23.46 and a beta of 0.33. Dr. Reddy's Laboratories Limited has a 52-week low of $12.26 and a 52-week high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The business had revenue of $996.17 million during the quarter, compared to analyst estimates of $83.70 billion. As a group, equities analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.